Clinical Study of an Ultrasound Renal Denervation System in Patients With Heart Failure

Inclusion Criteria : * Patients aged 18 years or older and younger than 85 years at the time of informed consent * NYHA (New York Heart Association) class II-III * More than 6 weeks have passed since onset of acute heart failure or acute exacerbation of chronic heart failure * Washout rate of MIBG \[3 (meta)-iodobenzylguanidine\] scintigraphy-cardiac is more than 35% * Patients having continued treatment of heart failure with the same dosage and administration for 4 weeks before obtaining informed consent Exclusion Criteria : * Patients with type1 diabetes mellitus, or uncontrolled type 2 diabetes mellitus (HbA1c: ≥ 8%) * Patients whose eGFR (estimated glomerular filtration rate) is less than 40 mL/min/1.73 m\^2 (estimation formula by Japanese Society of Nephrology) * Patients with concomitant or previous autoimmune or inflammatory bowel disease * Patients with a history of serious lung disease * Patients with a history of heart transplantation or VAD \[ventricle-assist device\] * Patients receiving reserpine, tricyclic antidepressants, and labetalol hydrochloride (can be used for up to 5 half-lives before informed consent is obtained) * Patients being treated for Parkinson's disease or Lewy body dementia * Patients with a history of any severe cardiovascular event (myocardial infarction, coronary artery bypass graft surgery, acute heart failure requiring hospitalization) or severe cerebrovascular event (stroke, transient ischemic event, cerebrovascular accident, etc.) within 3 months before obtaining informed consent * Patients with persistent atrial fibrillation * Patients using active implantable medical devices * Patients with coronary or carotid artery diseases who were deemed necessary by the principal investigator / sub investigator to undergo surgery or PCI (Percutaneous Coronary Intervention) within 6 months after obtaining informed consent * Patients with contraindications, unacceptable anaphylactic reactions, or uncontrollable allergies to contrast media * Female patients who are pregnant or breastfeeding * Patients whose office blood pressure (systolic) is 100mmHg or lower at the time of screening test